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Background: Cervical carcinoma is the second most common cancer and is an important cause of death in
women worldwide. CCAAT/enhancer binding proteins (C/EBPs) are a family of transcription factors that regulate
cellular differentiation and proliferation in a variety of tissues. However, the role of C/EBPα gene in cervical cancer is
still not clear.
Methods: We investigated the expression of C/EBPα gene in cervical squamous cell carcinoma. C/EBPα mRNA level
was measured by real-time quantitative RT-PCR in cervical cancer tissues and their adjacent normal tissues. C/EBPα
protein level was measured by immunohistochemistry. Methylation in the promoter of C/EBPα gene was detected
by MALDI TOF MassARRAY. We transfected HeLa cells with C/EBPα expression vector. C/EBPα expression in HeLa
cells was examined and HeLa cell proliferation was measured by MTT assay and HeLa cells migration was analyzed
by matrigel-coated transwell migration assays.
Results: There were significant difference in C/EBPα protein expression between chronic cervicitis and cervical
carcinoma (P < 0.001). CEBPα mRNA level was significantly lower in cervical cancer tissues than in normal cervical
tissues (P < 0.01). Methylation of the promoter of CEBPα gene in CpG 5, CpG-14.15, CpG-19.20 were significantly
higher in cervical cancer than in normal cervical tissues (P < 0.05, P < 0.01, P < 0.05, respectively). CEBPα pcDNA3.1
construct transfected into HeLa cells inhibited cell proliferation and decreased cell migration.
Conclusions: Our results indicate that reduced C/EBPα gene expression may play a role in the development of
cervical squamous cell carcinoma.
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Cervical carcinoma is the second most common cancer
and is an important cause of death in women worldwide
[1]. The incidence and mortality of cervical cancer have
decreased gradually in the past decades globally. In
China, however, the incidence of cervical cancer remains
high, particularly in young women [2].* Correspondence: panteacher89@sina.com
1Department of Biochemistry and Molecular Biology, School of Medicine,
Shihezi University, Xinjiang Endemic and Ethnic Disease and Education
Ministry Key Laboratory, Shihezi, Xinjiang 832002, China
2Department of Biochemistry and Molecular Biology, Basic Medical Science
of Tongji Medical College, Huazhong University of Science and Technology,
Wuhan, Hubei 430030, China
Full list of author information is available at the end of the article
© 2014 Pan et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.CCAAT/enhancer binding proteins (C/EBPs) are a
family of transcription factors with six members, α to ζ;
C/EBPs regulate cellular differentiation in a variety of
tissues [3]. Each C/EBP consists of an activation domain,
a DNA-binding domain, and a leucine-rich dimerization
domain. C/EBPα protein interacts with several cell-cycle
regulatory proteins; such interaction can inhibit cell pro-
liferation. For instance, C/EBPα interacts with retino-
blastoma (Rb) family proteins and inhibits cell growth
[4]. Studies showed that C/EBPα can form a complex with
cyclin-dependent kinase 2 (cdk2) and cyclin-dependent
kinase 4 (cdk4) proteins and block cyclin-cdk interactions
and cell cycle progression [5]. Aberrant expression of C/
EBPα in Trib1-deficient bone marrow cells is responsible. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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addition, it was suggested that high levels of C/EBPα
accelerate both the switching process and the cell
growth arrest [7]. C/EBPα gene was down-regulated in
many tumors such as skin carcinomas, breast cancer
and lung cancer [8]. C/EBPα gene as a lung tumor sup-
pressor was demonstrated: loss of C/EBPα expression
through p38α inactivation led to tumor promotion and
progression [9].
In our early work, we used suppression subtractive
hybridization method and found C/EBPα gene expres-
sion changed in cervical carcinoma tissues [10]. In
addition, Ko found that C/EBPδ gene expression level
decreased in cervical cancer [11]. We show here that C/




Clinical data and cervical squamous cell carcinoma sam-
ples were collected from patients at the First Affiliated
Hospital and the Third Affiliated Hospital of the Medical
College of Shihezi University, Xinjiang, China between
January 2008 and April 2012. Cervical cancer samples
were taken for every consecutive patient with different
grades of pathology. None of these patients received
chemotherapy or radiotherapy before the cervical tissue
samples were obtained. All histological diagnoses were
confirmed by experienced pathologists in the hospitals.
Written informed consent was obtained from each pa-
tient; approval was obtained from the Ethics Committee
of the Medical College of Shihezi University, China. Cer-
vical squamous cell carcinoma tissues and adjacent nor-
mal cervical tissues were collected together from each
patient. Tissue samples were snap-frozen immediately
after removal and were stored at −80°C.
Immunohistochemistry staining
Representative formalin fixed paraffin-embedded tissue
blocks were selected. Five μm sections were cut, deparaf-
finised and rehydrated through graded alcohols. Antigen
retrieval was performed by heating the slides in citrate
buffer at 98°C for 30 min in a water bath. Endogenous
peroxidase was quenched for 10 min with peroxidase
blocking reagent (Dako Corporation). Primary antibodies,
anti-C/EBPα (1:200; sc-61, Santa Cruz Biotechnology) and
anti-Ki-67 (1:100; BD Biosciences Pharmingen) were in-
cubated for 60 min at room temperature. Antibody
staining was visualized using the ChemMate Envision
detection system (Dako Cytomation). Sections were
counterstained. The counterstaining was performed with
Meyer’s hematoxylin solution. Negative controls were run
simultaneously with preimmune immunoglobulin. Rabbit
polyclonal antibody (Ab-1) used was diluted 10- and 50-fold. The specificity of the immunohistochemical reac-
tions was assessed by performing the assays in the
presence of an excess of relevant versus irrelevant pep-
tides. The peptide used for immunization completely
suppressed staining whereas an irrelevant peptide at
the same concentration had no effect. The C/EBPα
protein and Ki-67 protein IHC signal was scored on
the following scale taking into account both the pro-
portion of cells stained and the intensity of staining in
those cells as follows: score 0, no cells stained; score 1,
weak or absent nuclear staining and <5% of cells contain-
ing C/EBPα and Ki-67 localized to the nuclei of cells;
score 2, nuclear staining and between 5% and 25% of
the cells containing C/EBPα and Ki-67 localized prom-
inently to the nuclei of cells; score 3, nuclear staining
and between 26% and 50% of the cells containing C/
EBPα and Ki-67 localized prominently to the nuclei of
cells; score 4, nuclear staining and more than 50% of the
cells containing C/EBPα and Ki-67 localized pro-
minently to the nuclei of cells. Two observers quantified
independently.
Quantitative reverse transcription-PCR (qRT-PCR)
Total RNA was isolated from cervical squamous cell car-
cinoma tissues and their adjacent normal tissues using
the RNA Extraction Kit (Invitrogen). cDNA were synthe-
sized with Invitrogen's SuperScript One-Step RT-PCR
Kit; each reaction contained 2 μg total RNA, 2 μl Oligo
(dT) (500 μg/ml), and 7.5 μl DEPC water. Reactions
were heated for denaturation at 65°C for 5 min, then
quenched on ice for 5 min. The following reagents were
then added to each reaction: 4 μl 5× 1st Buffer, 2 ul 0.1
M DTT, 1 μl dNTPs (10 mM each), 0.5 μl RNase In-
hibitor (40 U/μl), 1 μl M-MLV (200 U/μl); the total vol-
ume of each reaction was 20 μl. The reactions were
kept at 25°C for 10 min, 37°C 1 h, and then 70°C for 10
min to terminate the reaction. C/EBPα mRNA level
was determined by real-time RT-PCR using a Light Cy-
cler 480 (Roche Diagnostics) with the forward primer,
5′-AACACGAAGCACGATCAGTCC-3′, and the re-
verse primer, 5′-CTCATTTTGGCAAGTATCCGA-3′.
The amplicons were 211 bp in size. To normalize the
amount of cDNA in each sample, the housekeeping
gene aldehyde-3-phosphate dehydrogenase (GAPDH)
was quantified on the control of experiment with spe-
cific primers (forward: 5′-TGTTGCCATCAATGAC
CCCTT-3′; reverse: 5′-CTCCACGACGTACTCAGC
G-3′); the amplicons were 202 bp. Each reaction con-
tained cDNA 500 ng, 2× PCR buffer for EvaGreen 10 μl,
20× EvaGreen 0.6 μl, forward primer and reverse primer
were 0.6 μl (10 uM/) respectively, Cap Taq polymerase 0.3
μl (5 U/μl); add DEPC water to 20 μl. Reaction conditions
were: initial denaturation for 5 min at 95°C; then 40 cycles
of denaturation for 15 sec at 95°C, primer annealing
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UPL fluorescence measurement for 3 sec at 76°C.Gene methylation analysis by matrix assisted laser
desorption ionization time of flight MassARRAY (MALDI-
TOF MassARRAY)
Gene methylation was analyzed using MALDI-TOF
MassARRAY method [12]. DNA from cervical tissue
samples was extracted using QIAamp DNA Mini Kit
(QIAGEN). Bisulfite treatment was performed using EZ
DNA methylation kit (Sequenom, USA). PCR was per-
formed in a total volume of 5 μl containing 0.5 U Hot
Star Taq polymerase (Qiagen), 10 pmol of forward and
reverse primers 0.5 μl, 10× PCR buffer (Mg2+ free) 0.5
μl, ddH2O 0.5 μl, MgCl2 0.4 μl, 25mM dNTP 0.1 μl and
5 ng template. Cycling was performed using a Mastercy-
cler (Eppendorf ) under the following conditions: 15 min
at 94°C; 45 cycles at 94°C for 20 sec, annealing at 62°C
for 30 sec and extension 72°C for 1 min; and finally, ex-
tension at 72°C for 3 min. Shrimp alkaline phosphotase
(SAP) mixture (2 μl) was then added to each reaction.
The reactions were vortexed briefly, centrifuged at 3,000
rpm for 5 min, and incubated at 37°C for 20 min, and
85°C for 5 min.
RNA transcription was performed in a volume of 5 μl
containing RNase Free-ddH2O (3.15 μl), 5× T cleavage &
Polymerase buffer (0.89 μl), T7 RNA & DNA polymerase
(0.44 μl), T cleavage mix (0.24 μl), DTT (100 mM, 0.22
μl), and RNAase A (0.06 μl). After incubation at 37°C
for 3 hr, 6 mg Clean Resin (Sequenom) was added to de-
salt RNA. MassARRAY MS (Bruker-Sequenom USA)
was used to analyze the data.Cell culture and transfection
cDNA of C/EBPα gene was cloned into pcDNA3.1(−)
vector and confirmed by sequencing after cloning into
the pcDNA3.1(−) expression vector. HeLa cells were
initially obtained from ATCC (American Type Culture
Collection, Manassas, VA) and maintained in our lab.
Non-transfected HeLa cells and those transfected with
pcDNA3.1(−) were used as controls. HeLa cells were
plated at 1–2 × 105 cells per well in a six-well cell culture
plate 12–24 hr before the transfection. Two μg of C/EBPα
constructs and control plasmids pcDNA3.1 were mixed
with 6 μl of Lipofect AMINE 2000 (Invitrogen). The mix-
ture was incubated at room temperature for 20 min. After
washing the cells with 1× PBS, the DNA/ Lipofect AMINE
2000 mixtures were transferred to HeLa cells. Plasmids
pcDNA3.1 were also transferred into separate HeLa cells
as controls. Transfected HeLa cells were then incubated at
37°C in the 5% CO2 for 24 hr. The effect of C/EBPα over-
expression was determined by measuring immunofluores-
cence luciferase activity using an assay system accordingto the manufacturer’s protocol (Promega). Each experi-
ment was repeated with multiple batches of cells.
Cell survival rate assay using MTT
The survival rate of HeLa cells transfected by C/EBPα
pcDNA3.1 construct and pcDNA3.1, and non-transfected
HeLa cells, was determined using the 3-(3,4-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
The HeLa cells transfected with C/EBPα pcDNA3.1
constructs, transfected cells with pcDNA3.1, and non-
transfected HeLa Cells were seeded in 96-well plates
(Falcon; Becton Dickinson Labware) at 0.6 × 104 cells
per well in DMEM containing 10% FBS. The cells were
incubated for 24 hr at 37°C; the number of cells was
quantified with the MTT cell growth assay kit according
to the manufacturer’s instruction. Briefly, 20 μl of MTT
solution was added to each well, incubated for 4 hr, and
then scanned at 570 nm by microplate reader MTP-300
(Corona); the quantification was repeated 10 times. The
statistics were obtained from ten individual experiments
by analysis of variance.
Cell migration assays
Cells were serum-starved overnight. The top chambers
of 6.5 mm Corning Costar transwells (Corning, NY, New
York, USA) were loaded with 0.2 ml of cells (5 × 105
cells/ml) in serum-free media. DMEM media containing
20% FBS 0.6 ml was added to the bottom wells and the
cells were then incubated at 37°C overnight. Cells on the
top layer were removed and the images of the cells at
the bottom of the membrane were captured using a
canon camera microscope (×200). The statistics were
obtained from five individual experiments by analysis of
variance.
Statistics
Statistical analysis was performed using SPSS 17.0 soft-
ware. C/EBPα protein levels were compared between
cervical carcinoma and chronic cervicitis using non-
parametric test. C/EBPα mRNA level in cervical car-
cinoma tissues and the adjacent normal tissues was
analyzed by Student ‘t’ test. The promoter of C/EBPα
gene methylation by MALDI TOF MassARRAY method
was analyzed with Wilcoxon Rank Sum Test.
Results
C/EBPα protein level in cervical carcinoma tissues and
chronic cervicitis tissues
C/EBPα protein level was strongly positive (score 4) in
the nuclei of chronic cervicitis cells. There were 70
strong staining (score 4), 19 medium staining (score 3),
20 weak staining (score 2) and 16 negative staining
(score 0–1) in chronic cervicitis tissues. There were,
however, 44 strong staining (score 4), 59 medium
Figure 1 Expression level of C/EBPα protein in chronic cervicitis tissues and cervical carcinoma measured by immunohistochemistry
(200× Magnification). (A) chronic cervicitis (B) well-differentiated cancer (C) moderately differentiated cancer (D) poorly differentiated cancer.
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negative staining (score 0–1) in cervical carcinoma.
C/EBPα protein level was the highest in well-differentiated
cervical carcinoma, followed by moderately differentiated
cervical cancer, and was the lowest in poorly differentiated
cervical cancer (Figure 1). Thus, the difference between
chronic cervicitis and cervical carcinoma in C/EBPα pro-
tein level was significant (P < 0.001) (Table 1). C/EBPα pro-
tein level in the well-differentiated cervical carcinoma was
significantly higher than that in the moderately differenti-
ated cervical carcinoma. Further, C/EBPα protein level in
moderately differentiated cervical carcinoma was signifi-
cantly higher than that in poorly differentiated cervical
carcinoma (P < 0.001) (Table 2). Immunohistochemistry
staining of serial sections of tissues showed that expressionTable 1 Expression of C/EBPα protein in the chronic cervicitis
Tissues Number Score 4
Chronic cervicitis tissues 125 70
Cervical squamous cell carcinoma tissues 159 44of C/EBPα protein was increased whereas expression of Ki-
67 protein expression was reduced in chronic cervicitis.
However, in CIN3 (carcinoma in situ) and squamous cell
carcinoma, C/EBPα protein expression was decreased
whereas Ki-67 protein expression was increased (Figure 2).
Therefore, it is possible that C/EBPα protein could regu-
late cervical cell proliferation.
C/EBPα mRNA level in cervical carcinoma and normal
cervical tissues
Fifteen cervical carcinoma tissues and their corresponding
normal cervical tissues were examined for CEBPα gene
expression by real time quantitative RT-PCR. The aver-
age CEBPα mRNA level was 3.07 ± 1.04 in cervical cancer
tissues and 5.63 ± 2.98 in their corresponding normaltissues and cervical carcinoma tissues
Score 3 Score 2 Score 0-1
19 20 16 P < 0.001
59 34 22
Table 2 Expression level of C/EBPα protein in cervical squamous carcinoma of different grades of pathology
Tissues Number C/EBPα protein expression
Score 4 Score 3 Score 2 Score 0-1
Well differentiated carcinoma 38 13 9 10 6 P < 0.001
Moderately differentiated carcinoma 99 31 49 10 9
Poorly differentiated carcinoma 22 0 1 14 7
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vical tissues and their corresponding normal cervical tis-
sues was significant (t = −3.150, P < 0.01). Thus, the
expression of CEBPα gene was reduced significantly in
cervical carcinoma tissues.
Methylation in the promoter of C/EBPα gene analysis
Forty-seven cervical carcinoma tissues and 25 normal
tissues were analyzed for methylation in the promoter of
C/EBPα gene by MALDI TOF MassARRAY. We found
that the rate of C/EBPα gene methylation in CpG 5,Figure 2 C/EBPα staining coincides with cell proliferation related prot
with C/EBPα, Ki-67 antibodies as indicated (200×Magnification). (B) Two seria
Ki-67 antibodies as indicated (200×Magnification). (C) Two serial sections of t
C/EBPα, Ki-67 antibodies as indicated (200×Magnification).CpG-14.15, CpG-19.20 were significantly higher in cer-
vical tissues than in normal cervical tissues (P < 0.05,
P < 0.01, P < 0.05, respectively; Figure 3B). Methylation
in the promoter of C/EBPα gene, thus, may have caused
the reduction in the expression of this gene.
C/EBPα gene construct transfected into HeLa cells inhibit
cell growth and decrease cell migration
The proliferation of HeLa cells transfected by C/EBPα
pcDNA3.1 construct was inhibited significantly compared
to those transfected by pcDNA3.1 plasmid and non-ein Ki-67. (A) Two serial sections of a chronic cervicitis sample stained
l sections of the same sample showing CIN3 are stained with C/EBPα,
he same sample showing squamous cell carcinoma are stained with
Figure 3 Expression level of C/EBPα mRNA in cervical tissues. (A) C/EBPα mRNA expression was significantly reduced in cervical cancer
tissues than in normal cervical tissues, (P < 0.01) and marked by an asterisk. (B) The promoter of C/EBPα gene methylation rate in CpG 5,
CpG-14.15, CpG-19.20 were significantly higher than in normal cervical tissues (P < 0.05, P < 0.01, P < 0.05, respectively).
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ure 4A). This study indicates that C/EBPα gene may inhibit
HeLa cell proliferation. To assess whether overexpression
of C/EBPα is sufficient to reduce cell migration, we mea-
sured the migration of HeLa cells using transwell migration
assays. The number of HeLa cells migrated in C/EBPα
pcDNA3.1 construct transfected group is significantly less
than that in the two control groups, i.e. pcDNA3.1 plasmid
transfected group (without C/EBPα gene) and the HeLa
cells not subject to transfection (Figure 4B). Thus, the
expression of C/EBPα protein in HeLa appears to in-
hibit cell migration. The numbers of migration cells
are significantly different between C/EBPα pcDNA3.1
construct transfected group and the two control groups
with mean ± SD (n = 5) (P < 0.001) (Figure 4C).
Discussion
Proteins in the C/EBP family are fundamental to the
control of differentiation and proliferation of many adult
tissues. C/EBPα gene is involved in mitotic growth arrestand differentiation of numerous cell types. Down-
regulation of C/EBPα in keratinocytes can be permissive
for cell proliferation and may block squamous differenti-
ation. Reduction of C/EBPα gene expression occurred in
hepatocellular carcinoma, skin carcinoma and lung cancer,
in particular in lung adenocarcinomas, which had the
most significant and frequent reduction in C/EBPα gene
expression [4]. C/EBPα is aberrantly silenced in pancreatic
cancer cells and restored C/EBPα gene expression mark-
edly suppressed proliferation of pancreatic cancer cells
[13]. In gastric carcinoma, loss of C/EBPα is associated
with the switch from cellular differentiation to cellular
proliferation, presumably as a result of the activation of
Ras/MAPK pathway [14]. In addition, methylation in the
promoter of C/EBPα gene occurred at a rate of 24% in
dedifferentiated liposarcoma (DLPS). While treatment
with demethylating agents could restore C/EBPα expression
in DLPS cells, it was anti-proliferative and pro-apoptotic
in vitro and reduced tumor growth in vivo [15]. C/EBPα
gene is located in 19q13, gene loss at this site of
Figure 4 Inhibited growth and decreased migration of HeLa cells transfected with C/EBPα construct. (A) MTT Assay: equal numbers of
HeLa cells transfected with either empty vector (pcDNA3.1) and C/EBPα expression vector (pcDNA3.1- C/EBPα), and non-transfected cells (HeLa
cells), were grown in the serum-free DMEM medium. After 24 hours, cell proliferation was determined by MTT assays. Cell numbers between
pcDNA3.1-C/EBPα transfected groups and between pcDNA3.1 transfected and non-transfected groups were significantly different with mean ± SD
(n = 10) (P < 0.001). (B) The photographs show a representative field from each of the cell lines that have migrated into the chamber. pcDNA3.1-
C/EBPα group cell migration is reduced than pcDNA3.1 vector and non transfected HeLa cells. (C) In the lower panel, The number of migration
of HeLa cells is calculated among three groups. C/EBPα reduced migration is statistically significant with mean ± SD (n = 5) (P < 0.001), and marked
by an asterisk.
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ferentiated liposarcoma (DDLS) [16].
Disease-specific survival was shorter for patients with
19q13 loss than for patients with diploid 19q13 [16]. Com-
mon copy-number losses were associated with transcrip-
tional down-regulation of C/EBPα gene [16]. C/EBPα can
interact with some genes and affect cell activities [17].
Restoration of C/EBPα in Yin-Yang-1 (YY1) gene express-
ing hepatocellular carcinoma (HCC) cells induced cellular
differentiation and growth inhibition, while knockdown of
C/EBPα expression in non-tumor liver cells promoted cell
growth. Therefore, it indicted that YY1 gene couldpromote hepatocellular carcinogenesis and inhibit cellular
differentiation through the down-regulation of C/EBPα
expression [17]. There is evidence that C/EBPα exerts its
effects, in part, by regulating specific micro RNAs, such as
miR-223 [18]. miR-511 and miR-1297 act as tumor sup-
pressor genes, which could suppress lung adenocarcinoma
A549 cell line proliferation in vitro and in vivo by sup-
pressing tribbles homolog 2 (TRIB2) gene and further in-
creasing C/EBPα gene expression [19]. It showed that
NAD(P)H:quinone oxidoreductase 1 (NQO1) gene con-
trol of C/EBPα against 20S proteasome degradation
contributed to the up-regulation of p63 expression and
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induced skin cancer [20].
In the mouse model of AML, C-terminal C/EBPα muta-
tions increase the proliferation of long-term hematopoietic
stem cells (LT-HSC) whereas N-terminal C/EBPα muta-
tions allow formation of leukemia initiating cells [21].
The evidence available indicates that impaired C/EBPα
function contributes directly to the development of
AML; thus restoring C/EBPα function represents a prom-
ising target for novel therapeutic strategies in AML [22].
The consequential up-regulation of C/EBPα and IGFBP-
5 by curcumin is crucial to the suppression of oral
carcinogenesis [23]. In acute promyelocytic leukemia
cancer-initiating cells, C/EBPα expression is down-
regulated, possibly through a methylation-dependent
mechanism, indicating that C/EBPα deregulation may
contribute to the transformation of these cells [24].
The ectopic expression of C/EBPα can induce the
monocytic differentiation of myelomonocytic leukemic
cells through the down-regulation of Myc gene [25].
The expression of C/EBPα gene in cervical cancer is
poorly understood. We found that C/EBPα protein expres-
sion was significantly different between chronic cervicitis
and cervical squamous cell carcinoma. Moreover, the ex-
pression level of C/EBPα protein in the well-differentiated
cervical carcinoma was significantly higher than that in the
moderately differentiated cervical carcinoma. Furthermore,
the expression level of C/EBPα protein in the moderately
differentiated cervical carcinoma was higher than that
in the poorly differentiated cervical carcinoma. Clearly,
C/EBPα protein expression level was related to the grade
of pathology. Our results indicate that we may be able to
interfere the carcinogenesis of cervical cancer by regulat-
ing the expression of C/EBPα gene. Thus, C/EBPα protein
could potentially be a target for cervical cancer treatment
and changes in the expression of C/EBPα protein could be
of significance to the early diagnosis of cervical cancer.
In addition, C/EBPα protein increased expression whereas
Ki-67 protein decreased expression in chronic cervicitis
tissues. However, C/EBPα protein decreased expression
whereas Ki-67 protein increased expression in cancer
tissues (Figure 2). Thus, C/EBPα may affect cervical cell
proliferation. These results are similar to that obtained
by MTT assay of HeLa cells (Figure 4C).
We analyzed the C/EBPα mRNA expression in cervical
squamous cell carcinoma and their corresponding nor-
mal tissues. The C/EBPα mRNA expression level was
significantly higher in cervical squamous cell carcinoma
tissues than in their corresponding normal cervical tis-
sues. Our results indicated that C/EBPα mRNA expres-
sion level was decreased in invasive cervical cancer. In
addition, methylation in the promoter of C/EBPα gene
in cervical cancer tissues was significantly higher than in
normal cervical tissues. It is possible that the methylationin the promoter of C/EBPα gene leads to decreased ex-
pression of this gene.
The full length mRNA of C/EBPα gene was cloned in
pcDNA3.1 eukaryotic expression vector. The C/EBPα
gene construct and pcDNA3.1 vector were transfected
into HeLa cells. HeLa cells transfected by C/EBPα gene
construct were significantly lower in growth than the
HeLa cells transfected by pcDNA3.1 plasmid and the
non-transfected HeLa cells by MTT assay. In addition,
after being transfected by C/EBPα gene construct, the
migration of HeLa cells was significantly reduced than
those transfected by pcDNA3.1 plasmid and the non-
transfected HeLa cells by matrigel-coated transwell mi-
gration assays. These results indicate that C/EBPα gene
may inhibit the growth of HeLa cells and decrease the
invasion of HeLa cells. Therefore, C/EBPα gene may act
as a tumor suppressor gene for cervical carcinoma.
Conclusions
In summary, the expression of C/EBPα gene and C/EBPα
protein was down-regulated in cervical carcinoma tissues,
possibly caused by methylation in the promoter region
of this gene. Reduced expression of C/EBPα gene and
C/EBPα protein appears to be associated with cervical
tumorigenesis. By gene transfection methods, we showed
that C/EBPα gene could inhibit the growth of HeLa cells
and reduce the invasion of HeLa cells. Therefore, C/EBPα
gene may be a tumor suppressor gene in HeLa cells and
plays an important role in cervical carcinogenesis.
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